Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2-breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

被引：8

作者：

Prat, A. ^{[1
]}

Falato, C. ^{[2
]}

Pare Brunet, L. ^{[3
]}

Martinez Saez, O. ^{[4
]}

Cejalvo Andujar, J. M. ^{[5
]}

Margeli Vila, M. ^{[6
]}

Tolosa, P. ^{[7
]}

Salvador Bofill, F. J. ^{[8
]}

Cruz Jurado, J. ^{[9
]}

Gonzalez-Farre, B. ^{[10
]}

Sanfeliu Torres, E. ^{[10
]}

Ciruelos, E. M. ^{[11
]}

Espinosa-Bravo, M. ^{[12
]}

Izarzugaza Peron, Y. ^{[13
]}

Pernas Simon, S. ^{[14
]}

Esker, S. ^{[15
]}

Fan, P-D. ^{[16
]}

Ferrero Cafiero, J. M. ^{[17
]}

Pascual, T. ^{[18
]}

Oliveira, M. ^{[19
]}

机构：

[1] Hosp Clin Barcelona SOLTI IDIBAPS, Dept Med Oncol, Barcelona, Spain

[2] IDIBAPS August Pi Sunyer Biomed Res Inst, SOLTI Canc Res Grp, Barcelona, Spain

[3] SOLTI Canc Res Grp, Data Management, Barcelona, Spain

[4] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Canc Res Grp, Barcelona, Spain

[5] Hosp Clin Univ Valencia, Dept Med Oncol, SOLTI Canc Res Grp, Valencia, Spain

[6] ICO Inst Catala Oncol Badalona Hosp Univ Germans, Dept Med Oncol, SOLTI Canc Res Grp, Badalona, Spain

[7] Inst Invest Sanitaria Hosp 12 Octubre, Dept Med Oncol, SOLTI Canc Res Grp, Madrid, Spain

[8] Hosp Univ Virgen Valme, Med Oncol, Seville, Spain

[9] Hosp Univ Canarias, Dept Med Oncol, San Cristobal, Spain

[10] Hosp Clin Barcelona, Pathol Dept, SOLTI Canc Res Grp, Barcelona, Spain

[11] Hosp Univ 12 Octubre, Dept Med Oncol, SOLTI Canc Res Grp, Madrid, Spain

[12] Vall dHebron Univ Hosp, Breast Surg Unit, Barcelona, Spain

[13] Hosp Univ Fdn Jimenez Diaz, Dept Oncol, Madrid, Spain

[14] ICO Inst Catala Oncol Hosp Hosp Duran, Dept Med Oncol, SOLTI Canc Res Grp, Lhospitalet De Llobregat, Spain

[15] Daiichi Sankyo Inc, Global Med Dept, Basking Ridge, NJ USA

[16] Daiichi Sankyo Pharma Dev USA, Global Oncol, Edison, NJ USA

[17] SOLTI Canc Res Grp, Dept Clin Res, Barcelona, Spain

[18] Hosp Clin Barcelona, Dept Med Oncol, SOLTI Canc Res Grp, Barcelona, Spain

[19] Vall dHebron Inst Oncol VHIO, SOLTI Canc Res Grp, Breast Canc Unit, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.279

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA3

引用

页码：S164 / S164

页数：1

共 50 条

[41] Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).
Krop, Ian E.
Masuda, Norikazu
Mukohara, Toru
Takahashi, Shunji
Nakayama, Takahiro
Inoue, Kenichi
Iwata, Hiroji
Toyama, Tatsuya
Yamamoto, Yutaka
Hansra, Damien Mikael
Takahashi, Masato
Osaki, Akihiko
Koyama, Kumiko
Inoue, Tatsuya
Yonekura, Takatoshi
Mostillo, Joseph
Ohwada, Shoichi
Tanaka, Yoshimi
Sternberg, David W.
Yonemori, Kan
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[42] Escalating and de-escalating treatments in HR+HER2- early-stage breast cancer
Ge, Rui
TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
[43] Impact of endocrine therapy regimens for early-stage ER+/HER2-breast cancer on contralateral breast cancer risk
Sarkar, Swarnavo
Schechter, Clyde
Kurian, Allison W.
Caswell-Jin, Jennifer L.
Jayasekera, Jinani
Mandelblatt, Jeanne S.
NPJ BREAST CANCER, 2025, 11 (01)
[44] Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Yu, H. A.
Cantero, F.
Kim, B.
Lee, M.
Wu, E.
Sternberg, D. W.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1092 - S1093
[45] Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial
Bartsch, Rupert
Batista, Marta Vaz
Berghoff, Anna Sophie
Furtner, Julia
Marhold, Maximilian
Oberndorfer, Felicitas
Garde, Javier
Ruiz-Borrego, Manuel
Greil, Richard
Raimondi, Giulia
Campolier, Marta
Jimenez-Cortegana, Carlos
Gonzalez-Alonso, Paula
Sampayo-Cordero, Miguel
Llombart, Antonio
Fuereder, Thorsten
Preusser, Matthias
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[46] Targeting PAM50 HER2-Enriched intrinsic subtype with enzalutamide in hormone receptor- positive/HER2-negative (HR+/HER2-) advanced breast cancer: results of the SOLTI-1502 ARIANNA trial
Oliveira, Mafalda
Pascual, Tomas
Pernas, Sonia
Margeli, Mireia
Blanch, Salvador
Adamo, Barbara
Bofill, Francisco Javier Salvador
Gonzalez-Farre, Xavier
Chillara, Samyukta
Galvan, Patricia
Sanfeliu, Esther
Blasco, Paula
Sirenko, Valeria
Espinosa, Alejandra
Perou, Charles M.
Prat, Aleix
Manso, Luis
CANCER RESEARCH, 2024, 84 (09)
[47] MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis
Goetz, Matthew P.
Martin, Miguel
Di Leo, Angelo
Im, Seock-Ah
Awada, Ahmad
Forrester, Tammy
Frenzel, Martin
Cox, Joanne
Barriga, Susana
Toi, Masakazu
Iwata, Hiroji
Johnston, Stephen
CANCER RESEARCH, 2018, 78 (13)
[48] Continued efficacy of neratinib in patients with HER2-positive (HER2+) early-stage breast cancer: final overall survival (OS) analysis from the randomized phase 3 ExteNET trial
Martin, M.
Holmes, F. A.
Moy, B.
Mansi, J.
Gnant, M.
Buyse, M.
Barrios, C.
Bryce, R.
Wong, A.
Chan, A.
BREAST, 2021, 56 : S19 - S19
[49] Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy in previouslytreated, inoperable or metastatic HR+/HER2-breast cancer: TROPION-Breast01
Bardia, Aditya
Kalinsky, Kevin
Tsurutani, Junji
Hamilton, Erika
Sohn, Joo Hyuk
Park, Kyong Hwa
Park, Yeon Hee
Im, Seock-Ah
Lee, Keun Seok
Dastur, Daisy
Haddad, Vincent
Khan, Sabrina
Xu, Binghe
Pistilli, Barbara
Rugo, Hope
CANCER RESEARCH, 2023, 83 (05)
[50] MONARCH 3: Abemaciclib as initial therapy for patients with HR+/HER2-advanced breast cancer
Di Leo, A.
Toi, M.
Campone, M.
Sohn, J.
Paluch-Shimon, S.
Huober, J.
Park, I. H.
Tredan, O.
Chen, S-C.
Manso, L.
Freedman, O.
Jaliffe, G. G.
Forrester, T.
Frenzel, M.
Barriga, S.
Smith, I. C.
Bourayou, N.
Goetz, M. P.
ANNALS OF ONCOLOGY, 2017, 28

← 1 2 3 4 5 →